お知らせ • Jun 18
Acarix AB (Publ) Announces Directorate Appointments Acarix AB (publ) at its AGM held on 17 June 2026, approved election of Erik von Schenck and Marcin Golebicki as new directors. Board Change • May 20
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 5 experienced directors. No highly experienced directors. Independent Director Marlou Janssen-Counotte is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. お知らせ • Feb 13
Acarix AB (publ), Annual General Meeting, May 13, 2026 Acarix AB (publ), Annual General Meeting, May 13, 2026. お知らせ • Jun 26
Acarix Applauds New Peer-Reviewed Study Demonstrating Cost-Effectiveness of the CADScor®? System in U.S. Emergency Departments Acarix announced the publication of a new peer-reviewed study in PharmacoEconomics - Open demonstrating that the CADScor®? System is a cost-effective diagnostic tool for evaluating low-risk chest pain patients in U.S. emergency departments. The independent study, conducted by researchers from the Baim Institute for Clinical Research and leading academic hospitals in Boston, utilized a comprehensive economic model to compare the CADScor®? system with traditional noninvasive cardiac imaging methods. Results showed that a "CADScor-First" strategy could lead to substantial cost savings-estimated between $7.3 million and $15.3 million per 10,000 patients-without compromising patient safety. The CADScor®? System are FDA-cleared and uses advanced high fidelity acoustics and proprietary algorithms to assess the risk of obstructive coronary artery disease in under 10 minutes at the point of care. お知らせ • May 14
Acarix AB (Publ) Approves Election of Jan Poulsen as Director and Chair of the Board Acarix AB (publ) announced that at its AGM held on 13 May 2025, the shareholders approved election of Jan Poulsen as new director. Jan Poulsen was elected as chair of the board. お知らせ • Nov 12
Acarix AB (publ), Annual General Meeting, May 15, 2025 Acarix AB (publ), Annual General Meeting, May 15, 2025. Location: stockholm Sweden New Risk • Nov 10
New major risk - Revenue and earnings growth Earnings have declined by 15% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (36% average weekly change). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m (kr5.7m revenue, or US$525k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr70m). Shareholders have been diluted in the past year (46% increase in shares outstanding). Market cap is less than US$100m (€29.1m market cap, or US$31.2m). Reported Earnings • Nov 08
Third quarter 2024 earnings released: kr0.019 loss per share (vs kr0.038 loss in 3Q 2023) Third quarter 2024 results: kr0.019 loss per share. Revenue: kr993.0k (down 37% from 3Q 2023). Net loss: kr18.6m (loss widened 7.4% from 3Q 2023). Revenue is forecast to grow 101% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. New Risk • Aug 26
New major risk - Revenue and earnings growth Earnings have declined by 15% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (115% increase in shares outstanding). Revenue is less than US$1m (kr6.3m revenue, or US$612k). Minor Risk Market cap is less than US$100m (€23.4m market cap, or US$26.1m). Reported Earnings • Aug 23
Second quarter 2024 earnings released: kr0.02 loss per share (vs kr0.051 loss in 2Q 2023) Second quarter 2024 results: kr0.02 loss per share (improved from kr0.051 loss in 2Q 2023). Revenue: kr1.96m (up 27% from 2Q 2023). Net loss: kr16.7m (loss narrowed 24% from 2Q 2023). Revenue is forecast to grow 83% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings. お知らせ • Aug 13
Acarix Expands Within US Wellness Exam Market Acarix announced expanded use of the CADScor System within wellness exams as part of self-insured companies' health plans. As healthcare costs continue to rise, the CADScor System has now been proven to be an easy and quick strategy to risk stratify patients for significant coronary artery disease. The US employer self-insured market is rapidly expanding to include approximately 60 million Americans. In a self-funded insurance plan, companies bear the direct financial responsibility for their employee's healthcare costs and are acutely aware of the impact that serious health events, such as heart attacks, can have on their bottom line. Acarix has expanded its presence in the self-insured healthcare market, focusing on providing solutions for wellness exams. The first strategic account was signed with Delaware Resource Group, which successfully assessed its employees and families with the CADScor System. お知らせ • Jul 05
Acarix AB (publ) announced that it expects to receive SEK 21 million in funding Acarix AB (publ) announced a private placement to issue 60,000,000 common shares at an issue price of SEK 0.35 per share for the gross proceeds of SEK 21,000,000 on July 3, 2024. お知らせ • Jun 13
Acarix Announces Enrollment of First Patient in Us-Based Clinical Workflow Evaluation Study Acarix announced the enrollment of the first patient in its first US-based clinical study. The study aims to gather real-world data to compare workflows between traditional stress tests and the CADScor System. The focus is on identifying non-obstructive Coronary Artery Disease (CAD) in chest pain patients, with the ultimate goal of improving discharge from Emergency Departments and Clinics in the United States. The study is set to enroll 200 patients at the University of California, Davis, assessing the potential improvements in cost-effectiveness, time savings, and reduction in side effects by using the CADScor System compared to traditional stress imaging tests. This marks a crucial step in enhancing the understanding of the CADScor System's role in various clinical workflows across the United States. お知らせ • May 29
Acarix AB (Publ) Appoints Jeff Thomas as the New Head of US Sales, Effective June 1, 2024 Acarix AB (publ) announced appointment of Jeff Thomas as the new Head of US Sales, effective June 1st, 2024. With over two decades of sales experience in the medical device and healthcare industries, Thomas brings outstanding expertise and leadership to his new role, setting the stage for exciting new developments at Acarix. Throughout his career, Thomas has consistently delivered exceptional results, both in Fortune 100 companies and start-ups. His deep understanding of market trends in the healthcare sector, particularly in cardiovascular therapy, positions him as a strategic asset for Acarix. Thomas' broad experience at Biotronik Inc., St. Jude Medical, Guidant Corp. (now Boston Scientific), and other leading MedTech companies highlights his exceptional performance, leadership, and commitment to improving patient outcomes. Prior to joining Acarix, Thomas served as the Executive VP of Sales & Business Development at Vitalus Health, where he led all aspects of sales strategy, resulting in significant revenue growth and the expansion of the customer base. His achievements include developing and implementing revenue growth strategies, fostering a high-performance culture, and building key stakeholder relationships. Reported Earnings • May 15
First quarter 2024 earnings released: kr0.019 loss per share (vs kr0.045 loss in 1Q 2023) First quarter 2024 results: kr0.019 loss per share (improved from kr0.045 loss in 1Q 2023). Net loss: kr14.9m (loss narrowed 9.4% from 1Q 2023). Revenue is forecast to grow 71% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings. お知らせ • May 15
Acarix AB (publ) Approves Board Elections Acarix AB (publ) at its AGM held on May 14, 2024 approved election of Ken Nelson and Dr. Tony Das as new directors. お知らせ • Apr 11
Acarix AB Announces Initiation of the First Us-Based Clinical Workflow Evaluation Study Acarix AB announced the initiation of the first US-based clinical study to collect real-world data to compare workflows between traditional stress tests and the CADScor System. The focus is on identifying non-obstructive Coronary Artery Disease (CAD) in chest pain patients, with the ultimate goal of improving discharge from Emergency Departments and Clinics in the United States. The clinical study will collect data from 200 patients at the University of California, Davis, being assessed for chest pain in both the emergency department and outpatient cardiology clinic. The study will assess the potential improvement in cost-effectiveness, time savings, and reduction in side effects by utilizing the CADScor System to identify non-obstructive coronary artery disease in chest pain patients compared to traditional stress imaging tests. Patient enrollment for the study will commence in early Second Quarter 2024, marking a crucial step forward in advancing the understanding of the CADScor System in various clinical workflows in the United States. Board Change • Mar 01
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Ulf Rosén is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Feb 16
Full year 2023 earnings released: kr0.16 loss per share (vs kr0.31 loss in FY 2022) Full year 2023 results: kr0.16 loss per share. Revenue: kr6.24m (up 7.2% from FY 2022). Net loss: kr77.8m (loss widened 1.1% from FY 2022). Revenue is forecast to grow 89% p.a. on average during the next 2 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. お知らせ • Feb 15
Acarix Appoints New Members to the Advisory Board Acarix announced the appointment of three new advisors to its team. Joining the advisory board are Ken Nelson, known for his leadership in the MedTech space; Dr. Saumil R. Oza, MD, an experienced electrophysiologist from Ascension Medical Group; and Dave Braun, a strategic and customer-driven executive with over 40 years of experience working in startup and large company environments. Ken Nelson brings over two decades of experience in the digital health, medical device, and remote patient monitoring industries. As a partner in the Medtech Advantage Fund and Chairman of the Board for CardiaCare, Mr. Nelson has played pivotal roles in numerous disruptive cardiac digital health and MedTech startups worldwide. His track record includes leadership positions in top market share players such as BioTelemetry, iRhythm, and Bardy Diagnostics. Dr. Saumil R. Oza, MD, is an electrophysiologist practicing in Jacksonville, FL, with over 15 years of experience and numerous publications. Renowned as a national expert in cardiology, Dr. Oza serves on advisory boards for established companies like Boston Scientific, Johnson and Johnson, GE, and Novo Nordisk, as well as biotech startups. His clinical and business expertise will provide the Acarix team with a fresh new viewpoint of the U.S. market. Dave Braun, a strategic, customer-driven entrepreneur with over four decades of leadership experience, joins Acarix as an advisor. His extensive background in strategic business planning, mergers and acquisitions, banking and investor relations, organization development, and team building will bring a fresh perspective to operational strategies. Adding these three advisors emphasizes Acarix's commitment to driving innovation in cardiac health while expanding its reach in the United States. The new advisory board members will enhance efforts to develop solutions that improve patient outcomes and advance the standard of care in cardiac diagnostics. お知らせ • Feb 02
Acarix AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 33.667038 million. Acarix AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 33.667038 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 181,005,581
Price\Range: SEK 0.186 お知らせ • Feb 01
Acarix AB (publ) Announces CEO Changes The Board of Acarix AB (publ) announced the appointment of Aamir Mahmood as new CEO with immediate effect, starting February 1, 2024. Mr. Mahmood succeeds Acting CEO Fred Colen as well as Helen Ljungdahl Round who has decided not to return to her position later in 2024. Aamir Mahmood has more than twenty years of experience in corporate leadership in the medical device industry with a successful track record of Global commercial roles in cardiovascular device markets, including sales, marketing and strategy functions at LivaNova, Boston Scientific, and Merck. Aamir presently serves as General Manager/Vice President Americas of MicroPort CRM. MicroPort is an industry leader in the field of pacemakers and other cardiac devices used for diagnosis, treatment and management of heart rhythm disorders and heart failure. Prior to running the Americas for MicroPort, Aamir rotated through two Ex Pat assignments in Europe running Global Sales followed by Global Marketing & Strategy. Aamir has an MBA and is a member of Young Presidents’ Organization (YPO). Aamir succeeds Helen Ljungdahl Round who was appointed CEO of Acarix in January of 2022. Under Helen’s leadership Acarix established a subsidiary and commercial team in the US market, secured key commercial contracts with the Veterans Affairs Health Administration, published a clinical framework for use of the CADScor System in collaboration with the American College of Cardiology (ACC), and raised growth capital from a broad base of investors to enable further market expansion. Aamir Mahmood assumed the CEO position on February 1, 2024. お知らせ • Nov 24
Acarix AB (publ) Advances the Utilization of Its CADScor System Within the Veterans Administration (Va) Healthcare Network Acarix AB (publ) announced an advancement in the utilization of its CADScor System within the Veterans Administration (VA) Healthcare network. The Southeast Louisiana VA Healthcare System has reordered CADScor Patches in their Slidell and Baton Rouge locations to be used with the CADScor System for risk-stratification of symptomatic patients suspected of coronary artery disease (CAD) throughout various facilities within their system. The Southeast Louisiana VA Healthcare System was the first VA location to place orders for CADScor System and patches in February, with approval of the CADScor System into their Standard Operating Procedure (SOP) in August. Since integrating the CADScor System into their SOP, the Southeast Louisiana VA Team has also aligned their Computerized Patient Record System (CPRS) with the SOP to ensure all relevant symptomatic patients suspected of CAD undergo a CADScor System Test. In the past few months, the Acarix team has collaborated closely with the Southeast Louisiana VA Leadership Team, providing support to more than 100 Healthcare Professionals (HCPs) through various activities, including CADScor System in-servicing within their Cardiology group. Furthermore, the team has been actively engaged in monthly Primary Care meetings with the Chief of Cardiology, effectively developing awareness about the CADScor System. New Risk • Nov 14
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr77m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr77m free cash flow). Share price has been highly volatile over the past 3 months (39% average weekly change). Shareholders have been substantially diluted in the past year (188% increase in shares outstanding). Revenue is less than US$1m (kr6.7m revenue, or US$620k). Minor Risks Currently unprofitable and not forecast to become profitable next year (kr14m net loss next year). Market cap is less than US$100m (€15.5m market cap, or US$16.6m). Reported Earnings • Nov 10
Third quarter 2023 earnings released: kr0.038 loss per share (vs kr0.084 loss in 3Q 2022) Third quarter 2023 results: kr0.038 loss per share (improved from kr0.084 loss in 3Q 2022). Revenue: kr1.57m (up 35% from 3Q 2022). Net loss: kr17.3m (loss narrowed 18% from 3Q 2022). Revenue is forecast to grow 99% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. お知らせ • Oct 19
Acarix AB (publ) has completed a Composite Units Offering in the amount of SEK 54.344161 million. Acarix AB (publ) has completed a Composite Units Offering in the amount of SEK 54.344161 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 90,573,602
Price\Range: SEK 0.6
Transaction Features: Rights Offering Reported Earnings • Sep 01
Second quarter 2023 earnings released: kr0.051 loss per share (vs kr0.073 loss in 2Q 2022) Second quarter 2023 results: kr0.051 loss per share. Revenue: kr1.54m (down 8.3% from 2Q 2022). Net loss: kr22.0m (loss widened 20% from 2Q 2022). Revenue is forecast to grow 85% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. お知らせ • Aug 29
Acarix AB (Publ) Appoints Dr. Deepak R. Talreja Md as New Medical Advisor Acarix AB (publ) announced the appointment of Dr. Deepak R. Talreja, MD, as new Medical Advisor. With an impressive background in cardiology, Dr. Talreja brings a wealth of knowledge and expertise to Acarix, further strengthening the company's commitment to transforming early cardiac diagnostics through cutting-edge acoustic and AI-based technology. As a highly respected cardiologist expert, Dr. Talreja has been at the forefront of numerous groundbreaking research initiatives, pioneering advancements that have significantly impacted patient care and outcomes. He is a graduate of the University of Virginia School of Medicine, completed his Internship and Residency at Vanderbilt University Medical Center, and fellowship at the Mayo School of Medicine. Dr. Talreja is board certified by the American Board of Internal Medicine (ABIM) in cardiovascular disease, interventional cardiology, and internal medicine: He is currently the Medical Director of the Cardiovascular Service Line at Sentara Health. Dr. Talreja's vast experience and leadership experience in cardiac electrical system procedures, interventional cardiac procedures, heart conditions and overall cardiac patient care align very well with Acarix's mission to develop patient-focused innovative solutions that address some of the challenges in early cardiac healthcare. お知らせ • May 12
Acarix AB Elects Mikael Thorén as Director Acarix AB elected Mikael Thorén as new director at the AGM held on May 11, 2023. Reported Earnings • Apr 25
Full year 2022 earnings released: kr0.31 loss per share (vs kr0.37 loss in FY 2021) Full year 2022 results: kr0.31 loss per share. Revenue: kr5.82m (up 55% from FY 2021). Net loss: kr77.0m (loss widened 49% from FY 2021). Revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Reported Earnings • Feb 18
Full year 2022 earnings released: kr0.31 loss per share (vs kr0.37 loss in FY 2021) Full year 2022 results: kr0.31 loss per share. Revenue: kr5.82m (up 55% from FY 2021). Net loss: kr77.0m (loss widened 49% from FY 2021). Revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. お知らせ • Feb 17
Acarix AB (publ) to Report Fiscal Year 2022 Final Results on Apr 20, 2023 Acarix AB (publ) announced that they will report fiscal year 2022 final results on Apr 20, 2023 お知らせ • Feb 14
Acarix AB (publ) to Report Q4, 2022 Results on Feb 16, 2023 Acarix AB (publ) announced that they will report Q4, 2022 results at 8:00 AM, Central European Standard Time on Feb 16, 2023 お知らせ • Nov 16
Acarix AB (publ) to Report Q3, 2022 Results on Nov 16, 2022 Acarix AB (publ) announced that they will report Q3, 2022 results at 8:00 AM, Central European Standard Time on Nov 16, 2022 お知らせ • Sep 29
Acarix AB (publ) Announces Patient Enrollment Completed in the Filter-Scad Randomized Controlled Multi-Center Trial Acarix AB (publ) announced that the FILTER-SCAD study is a randomized controlled clinical trial including more than 2,000 patients with suspected coronary artery disease (CAD). The study has now successfully completed patient enrollment. The one-year follow-up period will assess the impact on cardiac events. Comprehensive study results will be submitted for publication in First Quarter 2024. The FILTER-SCAD study was initiated in 2019 with the goal to investigate the cost efficiency of using the CADScor®System to rule out patients with suspected stable CAD, by reducing the need of unnecessary additional diagnostic assessments, without compromising patient safety. The study is a prospective, randomized, controlled, parallel-group, multicenter study, with more than 2,000 randomized patients across five sites in Denmark, including Bispebjerg Frederiksberg University Hospital, and one site in Sweden at Skåne University Hospital in Lund. Results will include a comparison of cumulative number of non-invasive and invasive diagnostic tests in the intervention group versus the control group. An important secondary endpoint is the difference between the two treatment groups with regards to major adverse cardiac events at one year after randomization. Reported Earnings • Aug 26
Second quarter 2022 earnings released: kr0.073 loss per share (vs kr0.093 loss in 2Q 2021) Second quarter 2022 results: kr0.073 loss per share. Net loss: kr18.4m (loss widened 41% from 2Q 2021). お知らせ • Aug 22
Acarix AB (publ) to Report Q2, 2022 Results on Aug 25, 2022 Acarix AB (publ) announced that they will report Q2, 2022 results at 8:00 AM, Central European Standard Time on Aug 25, 2022 Reported Earnings • May 12
First quarter 2022 earnings released: kr0.059 loss per share (vs kr0.083 loss in 1Q 2021) First quarter 2022 results: kr0.059 loss per share. Net loss: kr14.8m (loss widened 27% from 1Q 2021). Board Change • Apr 29
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Chairman of the Board Philip Siberg was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. お知らせ • Apr 12
Acarix AB (publ), Annual General Meeting, May 11, 2022 Acarix AB (publ), Annual General Meeting, May 11, 2022, at 10:00 Central European Standard Time. Location: Baker & McKenzie Advokatbyrå's office on Vasagatan 7 Stockholm Sweden Agenda: To consider Presentation of the annual report and audit report and the group annual report and group audit report; to consider adoption of income statement and balance sheet and group income statement and group balance sheet; to consider appropriation of the Company's profit or loss in accordance with the adopted balance sheet and the adopted group balance sheet; to consider discharge of liability for the directors and the managing director; to consider Determination of the number of directors and auditors; to consider Determination of remuneration to the board of directors and the auditors; to consider Election of board of directors and auditors; to consider Resolution regarding adoption of principles for the nomination committee; to consider other matters. Reported Earnings • Feb 18
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: kr0.34 loss per share (up from kr0.51 loss in FY 2020). Net loss: kr51.7m (loss widened 25% from FY 2020). Revenue missed analyst estimates by 37%. Over the next year, revenue is forecast to grow 246%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings. お知らせ • Feb 10
Acarix Submits Breakthrough Designation Request with Food and Drug Administration for Heart Failure Diagnosis Acarix summited breakthrough designation request with FDA for heart failure diagnosis. Acarix expands its portfolio and submits a breakthrough designation request for its innovative technology for heart failure diagnosis with the Food and Drug Administration (FDA) in USA. Heart failure affects more than 6 million people in the USA at costs exceeding $30 billion per year. Yet millions remain undiagnosed and early detection is critical. The availability of a rapid and cost-effective diagnostic tool to help quickly guide early intervention has significant potential to improve clinical outcomes of heart failure. The new Acarix Seismo is an AI-powered, non-invasive system that offers a simple, rapid risk assessment for patients with suspected heart failure in less than 10 minutes. The breakthrough submission is based on clinical data generated from the Seismo study performed in Denmark. Heart failure is a progressive condition that worsens over time, if left untreated. Treatment options depend on the stage of heart failure, from lifestyle changes and medications in the early stages to implantation of cardiac devices and medications in later stages. With this FDA breakthrough submission, Acarix intends to strengthen its leading position using AI based technology in cardiac care and patient management. お知らせ • Feb 08
Acarix AB (Publ) Announces CE Approval and FDA Denovo of CADScor System Acarix announced the CADScor System has CE approval and FDA DeNovo clearance for early diagnosis of patients with chest pain and suspected coronary artery disease (CAD), reducing the need for costly and time-consuming diagnostics assessments in patients with low risk. More than hundred CADScor Systems are in daily clinical use, and over 10,000 patients have been evaluated. The US is the largest market for heart disease, and the potential for CADScor System is high. To capture this potential, Acarix is now entering the US in a structured approach with direct sales and commercial partners. Reported Earnings • Nov 14
Third quarter 2021 earnings released: kr0.076 loss per share (vs kr0.11 loss in 3Q 2020) Third quarter 2021 results: Net loss: kr10.7m (loss widened 20% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 21
Second quarter 2021 earnings released: kr0.093 loss per share (vs kr0.20 loss in 2Q 2020) Second quarter 2021 results: Net loss: kr13.1m (loss widened 26% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings. Executive Departure • May 20
Director has left the company On the 11th of May, Paolo Raffaelli's tenure as Director ended after 2.0 years in the role. We don't have any record of a personal shareholding under Paolo's name. A total of 4 executives have left over the last 12 months. Executive Departure • May 20
Director has left the company On the 11th of May, Johanne Braendgaard's tenure in the role of Director ended. We don't have any record of a personal shareholding under Johanne's name. A total of 4 executives have left over the last 12 months. Executive Departure • May 20
Director has left the company On the 11th of May, Anders Jacobson's tenure as Director ended after less than a year in the role. We don't have any record of a personal shareholding under Anders' name. A total of 4 executives have left over the last 12 months. Executive Departure • May 14
Chairman of the Board Werner Braun has left the company On the 11th of May, Werner Braun's tenure in the role of Chairman of the Board ended. We don't have any record of a personal shareholding under Werner's name. Werner is the only executive to leave the company over the last 12 months. Reported Earnings • May 12
First quarter 2021 earnings released: kr0.083 loss per share (vs kr0.21 loss in 1Q 2020) First quarter 2021 results: Net loss: kr11.7m (loss widened 8.4% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 24
Full year 2020 earnings released: kr0.51 loss per share (vs kr1.83 loss in FY 2019) Full year 2020 results: Net loss: kr41.5m (loss narrowed 11% from FY 2019). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Apr 11
Director recently bought €87k worth of stock On the 7th of April, Ulf Rosén bought around 644k shares on-market at roughly €0.14 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. お知らせ • Jan 14
Acarix AB (publ) Announces Positive Preliminary Data from the Exploratory SEISMO Study Acarix AB (publ) announced positive preliminary data from the exploratory SEISMO study, using its modified CADScor System on a potential heart failure application. The SEISMO trial was initiated in June 2018 to evaluate the possibility of developing an algorithm that can differentiate patients referred with suspicion of heart failure. The study, with in total 199 patients at two sites in Denmark, included the last patient in 2020. The SEISMO study showed a low prevalence of heart failure in patients referred for heart failure evaluation at an outpatient clinic, making a reliable and fast rule-out method highly relevant. The devices used in the SEISMO study are modified CADScor Systems obtaining additional seismocardiographic data, and the results from the final analysis of the study data is expected to be submitted for publication in second quarter 2021. お知らせ • Nov 26
Acarix Receives US Market Approval for the CADScor System Acarix AB (publ) announced that the US Food and Drug Administration (FDA) has approved the company's De Novo application for marketing approval of the CADScor®System in the US. The De Novo process is used for new products where there is no predicate device with a comparable indication in the US market to support a standard 510 (k) application. Acarix filed the De Novo application in November 2019. お知らせ • Nov 19
Acarix AB (Publ) Announces Positive Results from Acarix study presented at ISPOR Acarix AB (publ) announced that the company’s real-life data analysis, made in co-operation with clinics in Germany and Austria, is published as a poster presentation and abstract at ISPOR, the leading European conference for health economics and outcomes research, which is held virtually November 16-19, 2020. The study compared two patient sets, 1030 patients from Germany and Austria and 1501 from the DanNICAD-1 trial in Denmark and the conclusion reached is that In clinical trials, ultra-sensitive phonocardiography has proven to be a clinically relevant diagnostic measurement. The use in real world has demonstrated that neither patient demographics nor test results differ relevantly from the trial setting and that real-life data thus could be used for further economic modeling. Reported Earnings • Nov 15
Third quarter 2020 earnings released: kr0.11 loss per share Third quarter 2020 results: Net loss: kr8.88m (loss narrowed 22% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings. お知らせ • Sep 10
Acarix AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 56.00188 million. Acarix AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 56.00188 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 86,156,738
Price\Range: SEK 0.65
Transaction Features: Rights Offering お知らせ • Aug 08
Acarix AB (publ) to Report Q4, 2020 Results on Feb 18, 2021 Acarix AB (publ) announced that they will report Q4, 2020 results on Feb 18, 2021 
